Body Mass Index-Related Trends in Adverse Events with Enfortumab Vedotin: Analysis of a Pharmacovigilance Database and Medical Records.

چکیده اصلی

Enfortumab vedotin (EV) is an antibody-drug conjugate used to treat advanced urothelial carcinoma. Although effective, it frequently causes adverse events, particularly skin toxicity. Body mass index (BMI) has been suggested as a risk factor for EV toxicity, but evidence from large-scale studies remains limited. This study investigated the association between BMI and EV toxicity using a national pharmacovigilance database and single-center clinical data. Adverse event reports from the Japanese Adverse Drug Event Report (JADER) database (2004-2025) were stratified by BMI (<22 vs. ≥22 kg/m2). Reporting odds ratios were calculated, and event frequencies were compared using z-tests. Additionally, a retrospective review of medical records was conducted for 17 EV-treated patients at a single institution. Data on dosing and adverse events were collected, and Fisher's exact test was applied. In JADER, a BMI ≥22 kg/m2 was associated with increased reporting of skin disorders, pruritus, and toxic epidermal necrolysis (p < 0.05), whereas a BMI <22 kg/m2 was associated with more reports of pyelonephritis (p = 0.007). In the clinical cohort, patients with skin toxicity had a higher BMI (25.1 vs. 17.7 kg/m2, p = 0.004) and received higher EV doses relative to ideal body weight (IBW) (108.3 vs. 79.9%, p = 0.007) than those without skin toxicity. A high BMI was associated with an increased risk of certain EV-related skin toxicities, potentially exacerbated by dosing based on actual versus IBW, whereas a low BMI may increase susceptibility to infections such as pyelonephritis. Individualizing risk assessment and dosing based on patient physique may improve the safety and efficacy of EV therapy.

متن کامل اصلی